Toxicogenetics in drug development

Toxicology Letters

Volumn 120, Issue 1-3, 2001, Pages 281-291

  Park, B Kevin ^a   Pirmohamed, Munir ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Adverse drug reactions; Pharmacogenetics; Single nucleotide polymorphisms; Toxicogenetics

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; COTRIMOXAZOLE; SULFAMETHOXAZOLE; SULFONAMIDE;

CONFERENCE PAPER; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GENETIC ANALYSIS; GENETIC TOXICOLOGY; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SAMPLING;

CARBAMAZEPINE; CLINICAL TRIALS; DRUG HYPERSENSITIVITY; DRUG INDUSTRY; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SULFONAMIDES; TOXICOLOGY; VARIATION (GENETICS);

EID: 0035977883     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(01)00280-6     Document Type: Conference Paper

References (50)

1. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
2. Pharmacogenetics and drug metabolism
3. Testing drug response in the presence of genetic information: Sampling issues for clinical trials
4. An endotoxin-induced serum factor that causes necrosis of tumors
5. Stereoselective interaction between the R enantiomer of warfarin and cimetidine
6. Evolving pattern of drug-induced toxic epidermal necrolysis
7. Reactions of nitroso and hydroxylamine metabolites of sulphamethoxazole with reduced glutathione: Implications for idiosyncratic toxicity
8. Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins
9. The purine path to chemotherapy
10. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia
11. Cytochrome P450 polymorphisms are associated with reduced warfarin dose
12. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine
13. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy
14. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions
15. The effect of the CYP2C9 genetic polymorphisms on sulphamethoxazole N-hydroxylation
16. Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity
17. Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms
18. The immunogenetics of human infectious diseases
19. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment
20. A method for the detection of atypical forms of human serum cholinesterase. Determination of dibucaine numbers
21. Human P450 metabolism of warfarin
22. Pharmacogenetics of cancer therapy: Getting personal
23. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase
24. Incidence of adverse drug reactions in hospitalized patients - A meta-analysis of prospective studies
25. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
26. Genetics in drug discovery and development: Challenge and promise of individualizing treatment in common complex diseases
27. Getting the right drug into the right patient
28. Plasma cysteine and decreased reduction of nitroso sulphamethoxazole with HIV infection
29. Pharmacogenetics and pharmacogenomics: Why is this relevant to the clinical geneticist?
30. Idiosyncratic drug reactions: A mechanistic evaluation of risk factors
31. Relevance of induction of human drug-metabolizing enzymes: Pharmacological and toxicological implications
32. The role of drug disposition in drug hypersensitivity: A chemical, molecular and clinical perspective
33. The adverse effects of drugs
34. Carbamazepine hypersensitivity: Assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine
35. Adverse drug reactions
36. Association analysis of drug-metabolizing enzyme gene polymorphisms in HIV-positive patients with co-triomoxazole hypersensitivity
37. Mechanisms of adverse drug reactions
38. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions
39. Pharmacogenetics and the practice of medicine
40. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient
41. Anticonvulsant hypersensitivity syndrome: In vitro risk assessment
42. Genetic predisposition to phenytoin-induced birth defects
43. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: Catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes
44. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment
45. Interpretation of results from genetic studies of multifactorial diseases
46. Adverse reactions to co-trimoxazole in HIV-infection
47. Human erythrocyte thiopurine methyltransferase: Radiochemical microassay and biochemical properties
48. Genetic-traits in common diseases
49. Pharmacogenetics
50. Science, medicine, and the future: Pharmacogenetics